GALT Galectin Therapeutics Inc.

+0  (2%)
Previous Close 3.20
Open 3.21
Price To book 34.41
Market Cap 111.39M
Shares 34,064,000
Volume 542,891
Short Ratio 1.89
Av. Daily Volume 724,406

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released March 6, 2017.
Plaque psoriasis
Phase 2a primary endpoint not met - September, 27 2016.
Nonalcoholic steatohepatitis (NASH)
Phase 2a interim data released May 2016
moderate-to-severe plaque psoriasis.
Phase 2b top-line data due December 2017.
Non-alcoholic steatohepatitis (NASH) with cirrhosis

Latest News

  1. Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02
  2. Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings?
  3. Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings?
  4. Edward Lifesciences (EW) Q1 Earnings: A Surprise in Store?
  5. Can Mead Johnson (MJN) Spring a Surprise in Q1 Earnings?
  6. ResMed (RMD) Q3 Earnings: Disappointment in the Cards?
  7. IDEXX Laboratories (IDXX) Q1 Earnings: Surprise in Store?
  8. Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017
  9. Can Illumina (ILMN) Spring a Surprise this Earnings Season?
  10. 5 Drug Stocks That Could Be Big Winners this Earnings Season
  11. Integra LifeSciences (IART) Q1 Earnings: A Beat in Store?
  12. GNC Holdings (GNC) Q1 Earnings: Disappointment in Store?
  13. Galectin Therapeutics and Axovant Sciences See Stocks Rise on Investor Optimism
  14. Galectin Therapeutics (GALT) Looks Good: Stock Jumps 16.7%
  15. Can The Uptrend Continue for Galectin Therapeutics (GALT)?
  16. Akari Therapeutics, Galectin Therapeutics Receive Positive Financial News
  17. Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst'
  18. Edited Transcript of GALT earnings conference call or presentation 28-Mar-17 1:00pm GMT
  19. Galectin Therapeutics Reports 2016 Financial Results and Provides Business Update
  20. Galectin Therapeutics Issues Statement Regarding GALTW and GALTU